Q-omics provides the consensus-scored C2CD2 profile across patient tissues and cancer cell-line models. C2CD2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, C2CD2 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, C2CD2 RNA expression shows 19,960 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and COAD as cancer lineages where C2CD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C2CD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C2CD2 survival associations across molecular data types. C2CD2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C2CD2 RNA expression–survival associations across cancer types. High C2CD2 expression shows unfavorable associations in UVM, BRCA, LGG, ACC and LIHC, but favorable associations in LUAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for C2CD2 RNA expression.
This table summarizes C2CD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for C2CD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C2CD2 shows lower tumor expression in THCA, BRCA and KICH and higher tumor expression in COAD, KIRC and LIHC. The COAD box plot shows higher C2CD2 RNA expression in tumor versus normal tissue (log2 FC = +0.618, t-test p < 0.001).
This table shows molecular features associated with C2CD2 in patient tissues and cancer cell lines. In patient samples, C2CD2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, C2CD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BONE and UPPER_AERODIGESTIVE_TRACT.
